Innovent Biologics, Inc.
IVBXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$94,631 | -$1,144,411 | -$2,170,469 | -$2,728,755 |
| Dep. & Amort. | $419,768 | $385,103 | $319,422 | $204,747 |
| Deferred Tax | $0 | $0 | $0 | $50,385 |
| Stock-Based Comp. | $556,521 | $574,197 | $469,490 | $501,572 |
| Change in WC | $449,819 | $403,389 | $309,908 | -$90,283 |
| Other Non-Cash | -$44,453 | -$70,468 | -$847,155 | $37,491 |
| Operating Cash Flow | $1,287,024 | $147,810 | -$1,918,804 | -$2,024,843 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | $0 | -$1,119,385 | -$1,381,730 | -$1,847,516 |
| Net Acquisitions | $0 | $0 | $0 | -$630,144 |
| Inv. Purchases | $0 | -$9,414,467 | -$10,325,704 | -$10,337,888 |
| Inv. Sales/Matur. | $0 | $9,244,320 | $10,019,845 | $10,121,480 |
| Other Inv. Act. | -$1,165,411 | $290,870 | $252,404 | -$4,080 |
| Investing Cash Flow | -$1,165,411 | -$998,662 | -$1,435,185 | -$2,698,148 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$730,443 | $418,499 | $715,172 | $1,208,083 |
| Stock Issued | $84,312 | $2,255,116 | $2,131,059 | $3,950,520 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $39,499 | -$86,358 | $45,851 | -$155,242 |
| Financing Cash Flow | -$606,632 | $2,587,257 | $2,892,082 | $5,003,361 |
| Forex Effect | $12,682 | -$6,877 | $118,664 | -$197,140 |
| Net Chg. in Cash | -$472,337 | $1,729,528 | -$343,243 | $83,230 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $2,745,693 | $1,016,165 | $1,359,408 | $1,276,178 |
| End Cash | $2,273,356 | $2,745,693 | $1,016,165 | $1,359,408 |
| Free Cash Flow | -$418,388 | -$1,235,650 | -$3,300,534 | -$3,872,359 |